Find a study
Browse recruiting studies near you — free to check, always your choice.
119 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Depression
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Testing lumateperone added to usual care for major depressive disorder
📍 University of Alabama at Birmingham · Huntsville, AL · +24 more US sites · Get directions →
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
- Depression
The Role of mGluR5 in CBT-I
Testing how a brain receptor may affect CBT-I for insomnia in people with depression
📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Testing azetukalner compared with a placebo for adults with major depression
📍 Harmonex Neuroscience Research · Dothan, AL · +33 more US sites · Get directions →
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Depression
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Testing brain scan and EEG measures to predict response to depression treatment
📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
- Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Testing azetukalner versus a placebo for bipolar depression in adults
📍 Noble Clinical Research · Tucson, AZ · +27 more US sites · Get directions →
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
- Depression
Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures
Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?
- Depression
Dopaminergic Therapy for Anhedonia - 2
Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation
📍 Emory University Hospital · Atlanta, GA · Get directions →
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.
- Dementia / Alzheimer's
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia
📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
- Parkinson's disease
A Study of Buntanetap in Participants With PD
Testing the long-term safety of buntanetap in people with Parkinson’s
📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.
- Depression
Identifying and Treating Depression in the Orthopaedic Trauma Population
Testing how orthopedic trauma teams can screen for depression and treat it with medication
📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →
The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.
- Dementia / Alzheimer'sParkinson's disease
PET Imaging Evaluation of [11C]SY08
Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s
📍 MGH · Charlestown, MA · Get directions →
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.
- DepressionAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Studying how gut bacteria in pregnant people relates to depression and anxiety
📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- Parkinson's disease
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
Testing an injection for brain scans to study Parkinson’s disease and safety
📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.
- DepressionAnxiety
Nebulized Ketamine for the Treatment of Major Depressive Disorder
Testing a breathing mist of ketamine to reduce symptoms of major depression
📍 Maimonides Medical Center · Brooklyn, NY · Get directions →
This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
- Parkinson's disease
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Testing a Parkinson’s surgery approach to see if it is safe and works
📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
- Parkinson's disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s
📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- Depression
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Testing azetukalner against a placebo for major depression in adults
📍 IMA Clinical Research Phoenix · Phoenix, AZ · +39 more US sites · Get directions →
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
- Depression
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
Testing how ketamine changes brain chemicals in people with depression
📍 University of Pennsylvania · Philadelphia, PA · Get directions →
In the treatment of Major Depressive Disorder (MDD), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained efficacy, a better understanding of the mechanism of action is urgently needed.
- Depression
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Testing a deuterated psilocin-related medicine for major depression
📍 UAB Psychiatry and Behavioral Neurology · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
- DepressionAnxiety
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
Testing whether eating more country foods and cultural activities help Inuit adults with depression
📍 Aqqiumavvik Society · Arviat, Nunavut · Get directions →
This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease
📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Dementia / Alzheimer's
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia
📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
- Depression
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Testing brenipatide to see if it delays return of major depression symptoms
📍 Accellacare - Moorpark · Moorpark, CA · +31 more US sites · Get directions →
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into three periods as follows: a screening period that will last approximately 1 month, a treatment period that will last a minimum of 12 months, and the follow up period that will last approximately 2 months.
- DepressionAnxiety
Creatine for Depressed Male and Female Methamphetamine Users
Testing whether creatine helps depression and anxiety in people who use meth
📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
- Parkinson's disease
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s
📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →
This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.
- Dementia / Alzheimer's
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women
📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
- Depression
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
Comparing best step-by-step treatments for depression with anxiety
📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
- Dementia / Alzheimer's
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Testing whether yearly donanemab helps people with dementia after a prior study
📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Depression
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Testing an experimental medicine against a placebo for depression
📍 Lighthouse Psychiatry · Gilbert, AZ · +26 more US sites · Get directions →
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
- Depression
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
Testing how NAC and MBCT affect brain chemistry linked to depression in teens
📍 University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience · Cincinnati, OH · Get directions →
The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.
- Dementia / Alzheimer's
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Testing a drug called trontinemab for early Alzheimer’s disease dementia
📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
- Dementia / Alzheimer's
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease
📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Depression
Probiotic Administration for Adolescent Depression
Testing whether a probiotic affects brain and gut in teens with depression
📍 UCSF · San Francisco, CA · Get directions →
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
- Depression
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Testing how one dose of psilocybin affects self-focused thinking in depression
📍 Athinoula A. Martinos Center for Biomedical Imaging · Charlestown, MA · Get directions →
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
- Depression
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Testing how well a medicine works to treat depression with daytime sleepiness
📍 Clinical Research Site · Chino, CA · +12 more US sites · Get directions →
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
- Parkinson's disease
18F-DOPA II - PET Imaging Optimization
Testing an imaging scan to study Parkinson’s disease using PET
📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
- Depression
Neural Circuit Effects of Ketamine in Depression
Testing how ketamine affects brain activity and depression symptoms
📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
- Depression
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Comparing a drug called AXS-05 with bupropion to prevent depression relapse
📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
- Depression
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing whether adding NBI-1065845 helps prevent relapse of depression
📍 Neurocrine Clinical Site · Oceanside, CA · +17 more US sites · Get directions →
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
- Depression
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
Testing a brain stimulation treatment to help knee arthritis pain and depression
📍 UCLA Semel Institute - Neuropsychiatric Institute (NPI) · Los Angeles, CA · Get directions →
Osteoarthritis (OA) is a major public health problem, and involvement of the knee is especially disabling. Symptomatic knee OA has an incidence rate between 40 to 1,020 per 100,000 person years1 and is among the most common causes of disability worldwide.
- Depression
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing whether adding NBI-1065845 helps improve depression symptoms
📍 Neurocrine Clinical Site · Huntsville, AL · +9 more US sites · Get directions →
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Depression
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Testing a biomarker prediction tool to forecast depression treatment outcomes
📍 University of Calgary · Calgary, Alberta · Get directions →
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).
- Dementia / Alzheimer's
Epidemiology and Biomarker Study in Alzheimer's Disease
Studying how memory changes over time and blood test results in people with dementia
📍 Care Access - Houston · Houston, TX · Get directions →
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Parkinson's disease
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions
📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
- Depression
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
Testing two types of attention-bias training for adults with depression
📍 Institute for Mental Health Research · Austin, TX · Get directions →
The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: * Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM * Aim 1: establish that gamified ABM is at least as effective as traditional ABM.
- Depression
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Testing whether esketamine added to standard care reduces depression symptoms in teens with recent
📍 University of Alabama at Birmingham · Birmingham, AL · +5 more US sites · Get directions →
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.
- Dementia / Alzheimer's
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Testing whether a brain PET scan can predict worsening memory problems
📍 Endeavor Health Systems · Evanston, IL · Get directions →
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.
- Depression
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing an add-on treatment to see if it helps people with major depression symptoms
📍 Neurocrine Clinical Site · Chino, CA · +14 more US sites · Get directions →
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Depression
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Testing the long-term safety of an added treatment for major depression
📍 Neurocrine Clinical Site · Huntsville, AL · +39 more US sites · Get directions →
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia
📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- DepressionAnxiety
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
Testing a cognitive training program to see brain and thinking changes in people with depression or
📍 UC San Diego · San Diego, CA · Get directions →
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.
- Depression
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Testing a low-amplitude seizure treatment vs standard ECT for suicidal thoughts in depression
📍 Pine Rest Christian Mental Health Services · Grand Rapids, MI · Get directions →
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly less cognitive/memory side effects (no memory side effects were noted in our prior studies for 500mA and 600mA) and thus is more favorable in terms of side effects compared to RUL conventional pulse amplitude ECT, while maintaining better anti-suicidal effect.
- Depression
Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
Testing low-frequency repetitive brain stimulation for bipolar depression
📍 University Health Network Toronto Western Hospital · Toronto, Ontario · Get directions →
The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC. This work will develop the evidence supporting the use of LFR rTMS for individuals with treatment-resistant BD-DE who currently have limited treatment options to alleviate their suffering.
- Dementia / Alzheimer's
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Comparing tau brain scan images in different types of dementia
📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
- Depression
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Testing whether adding seltorexant to antidepressants helps depression and sleep in adults with
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
- Dementia / Alzheimer's
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Testing a drug combination to treat agitation in adults with Alzheimer’s
📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Depression
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Testing whether adding milsaperidone helps people with depression, and checking side effects
📍 Vanda Investigational Site · Phoenix, AZ · +20 more US sites · Get directions →
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
- Depression
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Testing a depression add-on treatment in people with major depression
📍 Scottsdale Research Institute · Phoenix, AZ · +38 more US sites · Get directions →
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Parkinson's disease
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
Studying how a brain imaging tracer binds in early Parkinson’s over 24 months
📍 UAB · Birmingham, AL · Get directions →
The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.
- Showing the first 60 of 119. Add filters or a location to narrow down.